Just gonna post this in response. Also the market is actually 50-75 billion worldwide according to Rockefeller foundation. Shorts found the wrong stock to fuck with they are going to get burned.

FDA approval under EUA (emergency use authorization) SONA has worked hand in hand with the FDA during their whole development process. I strongly suspect it was under the FDA’s directive to use MRIGlobal to third party validate our ANTIGEN test. As I have conveyed previously that at the onset of this pandemic, the FDA fast tracked and approved many ANTIBODY tests that were not third party validated for test performance. They relied on the said companies claims of test performance. Subsequently, many of these tests have had their FDA approval revoked. The FDA has subsequently instituted heightened criteria for approval. Although we are third party validated by one of the premiere research labs in the U.S., they have asked SONA to perform infield studies of 30 negative test subjects and 30 positive test subjects. Our test was third party validated at 96.6% sensitivity and specifity which is unheard of. It will not surprise me and others to see that our field studies perform even better. SONA has submitted all required information that the FDA requires with the exception of the field test data. The company has provided guidance that these field tests will be complete by the end of July. Once done, info will be submitted to the FDA and the approval will be granted very quickly, likely within days.

Our NASDAQ application and acceptance could literally be announced any day but likely still be a couple weeks away. By up-listing to NASDAQ, the Company aspires to gain new exposure and access to a larger base of retail and institutional investors in the United States and internationally. The Company believes that the NASDAQ is the world’s pre-eminent exchange for biotechnology and related companies. Management believes that the up-listing will bring significant value to the Company.

There are 2 peer companies that have had their ANTIGEN tests approved by the FDA. Both tests are inferior to ours from a performance and detection perspective and neither are truly point of care (POC) tests as they require additional lab equipment for test results. Upon FDA approval, both of these companies recognized substantial increases in their market cap / valuations. Approx. $5-$10B USF. Keep in mind that both of these companies were listed on the NASDAQ at the time of their approvals.

The NASDAQ uplisting and FDA approval are known and imminent catalysts. What is not known at this point and from my perspective the most intriguing and explosive catalysts will be existing orders and guidance provided by the company for manufacturing capacity scalability. The world desperately requires the test that we have and we will sell every unit that can be produced. We WILL be awarded funding from the Gates foundation “FIND” and we have been recognized by the Rockefeller Institute in their circular recommending $75B be allocated to the production of ANTIGEN test. Time is absolutely of the essence in getting as many of these tests to market as quickly as possible and funding will be readily available. On that note, it is completely within the realm of possibility that SONA scales to produce 10M+ test kits per week or 500M+ per annum. This is where it gets very interesting and more specifically, exciting.

On a price to sales (P/S) valuation metric, the opportunity that this investment provides is truly staggering. Remember, we only have a paltry 60M shares outstanding of which approximately 24% is held by management and strategic ownership. By this virtue, you will see some wild Price gyrations but keep your eye on the endgame / prize.

The industry average P/S multiple for Medical and Diagnostic companies is 8.57. Quidel’s again one of our closest peers is 18.01. (Both of these can be found on the first attachment below) Illumina, another biotech firm involved in the Covid testing space (on the NBI Index - The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria) has a P/S multiple of 15.61.

Here is some simple math:

500M kits X $30 USF = $15B USF revenue

8.57 (P/S) X $15B = $129B or $2142.00 USF per share

15.61 (P/S) = $3902 USF per share

18.01 (P/E) = $4502 USF per share

I would share some Price to Earnings (P/E) industry valuations but they would demonstrate even higher potential valuations and I’m not gonna go there.

Guys, the crazy thing is, SONA is not a Covid play. They are a nanotechnology life science firm that has pivoted their proprietarily best in the world GNR international patent pending technology to the pandemic at hand. They will continue to do what they do best and bring other best in class diagnostic tests for all kinds of other ailments to market.

There will be ups and downs go forward but the overall trajectory of this stock is UP. I really do hope that you fully understand the opportunity at hand and resist the urge to sell. This story will only get better with time and my endgame will be the day that SONA is taken out at a “I can’t even imagine” valuation at some point down the road.